NICE Recommends BioMarin’s Vimizim® (elosulfase alfa) for the Treatment of Morquio A Syndrome in England
23 nov. 2015 10h45 HE
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Nov. 23, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that The National Institute for Health and Care Excellence (NICE), NHS England and...